×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
XBIO – xenetic biosciences, inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
XBIO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/17
09:15 am
xbio
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Medium
Report
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
12/16
09:27 am
xbio
Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform [Yahoo! Finance]
Low
Report
Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform [Yahoo! Finance]
12/16
09:00 am
xbio
Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
Medium
Report
Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
12/5
12:56 pm
xbio
Xenetic Biosciences Inc (NASDAQ: XBIO) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
Low
Report
Xenetic Biosciences Inc (NASDAQ: XBIO) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
12/5
09:03 am
xbio
Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program [Yahoo! Finance]
Low
Report
Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program [Yahoo! Finance]
12/5
08:45 am
xbio
Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program
Medium
Report
Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program
11/22
09:26 am
xbio
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment [Yahoo! Finance]
Low
Report
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment [Yahoo! Finance]
11/22
09:15 am
xbio
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Low
Report
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
12/13
05:00 pm
xbio
Form 4 Xenetic Biosciences, For: Dec 11 Filed by: Kornberg Roger D.
Low
Report
Form 4 Xenetic Biosciences, For: Dec 11 Filed by: Kornberg Roger D.
12/13
05:00 pm
xbio
Form 4 Xenetic Biosciences, For: Dec 11 Filed by: Borisenko Grigory G.
Low
Report
Form 4 Xenetic Biosciences, For: Dec 11 Filed by: Borisenko Grigory G.
12/13
05:00 pm
xbio
Form 4 Xenetic Biosciences, For: Dec 11 Filed by: VINOGRADOV ALEXEY ANDREEVICH
Low
Report
Form 4 Xenetic Biosciences, For: Dec 11 Filed by: VINOGRADOV ALEXEY ANDREEVICH
12/13
05:00 pm
xbio
Form 4 Xenetic Biosciences, For: Dec 11 Filed by: Dastoor Firdaus J.
Low
Report
Form 4 Xenetic Biosciences, For: Dec 11 Filed by: Dastoor Firdaus J.
12/13
04:30 pm
xbio
Form 8-K Xenetic Biosciences, For: Dec 11
Low
Report
Form 8-K Xenetic Biosciences, For: Dec 11
11/13
08:30 am
xbio
Form 8-K Xenetic Biosciences, For: Nov 13
High
Report
Form 8-K Xenetic Biosciences, For: Nov 13
11/12
04:31 pm
xbio
Form 10-Q Xenetic Biosciences, For: Sep 30
High
Report
Form 10-Q Xenetic Biosciences, For: Sep 30
11/7
09:04 am
xbio
Form 8-K Xenetic Biosciences, For: Nov 01
Low
Report
Form 8-K Xenetic Biosciences, For: Nov 01
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
7/5
Form S-1/A Xenetic Biosciences,
39.2%
6/24 Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock 31.6%
8/5 Form 3 Xenetic Biosciences, For: Jul 19 Filed by: VINOGRADOV ALEXEY ANDREEVICH 9.4%
4/24 Xenetic Biosciences (XBIO) Investor Presentation - Slideshow [Seeking Alpha] 8.9%
4/2 Form 4/A Xenetic Biosciences, For: Sep 26 Filed by: Borisenko Grigory G. 5.1%
7/25 Form SC 13G Xenetic Biosciences, Filed by: Altium Capital Management LP 4.9%
1/21 Form SC 13G/A Xenetic Biosciences, Filed by: Empery Asset Management, LP 4.8%
7/29 Form SC 13D Xenetic Biosciences, Filed by: Opko Health, Inc. 4.1%
9/4 Form SC 13G Xenetic Biosciences, Filed by: SABBY MANAGEMENT, LLC 3.5%
1/13 Form SC 13G/A Xenetic Biosciences, Filed by: SABBY MANAGEMENT, LLC 3.3%
6/24 Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock 31.6%
8/5 Form 3 Xenetic Biosciences, For: Jul 19 Filed by: VINOGRADOV ALEXEY ANDREEVICH 9.4%
4/24 Xenetic Biosciences (XBIO) Investor Presentation - Slideshow [Seeking Alpha] 8.9%
4/2 Form 4/A Xenetic Biosciences, For: Sep 26 Filed by: Borisenko Grigory G. 5.1%
7/25 Form SC 13G Xenetic Biosciences, Filed by: Altium Capital Management LP 4.9%
1/21 Form SC 13G/A Xenetic Biosciences, Filed by: Empery Asset Management, LP 4.8%
7/29 Form SC 13D Xenetic Biosciences, Filed by: Opko Health, Inc. 4.1%
9/4 Form SC 13G Xenetic Biosciences, Filed by: SABBY MANAGEMENT, LLC 3.5%
1/13 Form SC 13G/A Xenetic Biosciences, Filed by: SABBY MANAGEMENT, LLC 3.3%
TOP News Decliners
7/16
Form 8-K Xenetic Biosciences, For: Jul 16
-51.6%
7/22 Xenetic Biosciences, Inc. Closes $15.0 Million Underwritten Public Offering and Completes Acquisition of Innovative CAR T Technology Platform -30.7%
5/15 Form S-1 Xenetic Biosciences, -27.3%
7/22 Form 8-A12B Xenetic Biosciences, -19.1%
7/2 Form 8-K Xenetic Biosciences, For: Jun 28 -18.8%
7/12 Form S-1/A Xenetic Biosciences, -17.8%
7/29 Form SC 13G Xenetic Biosciences, Filed by: Anson Funds Management LP -14.6%
2/11 Xenetic Biosciences, Inc. to Present at Noble Capital Markets' 16th Annual Investor Conference -10.3%
10/16 Xenetic Biosciences, Inc. to Present at BIO Investor Forum -9.7%
11/15 Xenetic Biosciences, Inc. Reports Third Quarter 2019 Financial Results and Provides Corporate Update -9.5%
7/22 Xenetic Biosciences, Inc. Closes $15.0 Million Underwritten Public Offering and Completes Acquisition of Innovative CAR T Technology Platform -30.7%
5/15 Form S-1 Xenetic Biosciences, -27.3%
7/22 Form 8-A12B Xenetic Biosciences, -19.1%
7/2 Form 8-K Xenetic Biosciences, For: Jun 28 -18.8%
7/12 Form S-1/A Xenetic Biosciences, -17.8%
7/29 Form SC 13G Xenetic Biosciences, Filed by: Anson Funds Management LP -14.6%
2/11 Xenetic Biosciences, Inc. to Present at Noble Capital Markets' 16th Annual Investor Conference -10.3%
10/16 Xenetic Biosciences, Inc. to Present at BIO Investor Forum -9.7%
11/15 Xenetic Biosciences, Inc. Reports Third Quarter 2019 Financial Results and Provides Corporate Update -9.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: